CM Life Sciences, Inc.
Status: Deal Closed
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $442.75M |
|---|---|
| IPO Date | Sep 2, 2020 |
| CEO | Eli D. Casdin |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Life sciences |
| IPO Geography | Global |
| Target Company | Sema4 |
| Deal Announced | Feb 10, 2021 |
| Deal Size, $M | $2,071.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Jul 21, 2021 |
| Amendment Vote | TBD |
| Closing Date | Jul 22, 2021 |
Formerly CMLF
WGS
SMFRW
| Price | $69.39 $2.10 |
|---|---|
| Last closing price | $71.04 |
| H/L, today | $68.01 / $71.46 |
| Volume, today | 458,453 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on CM Life Sciences, Inc.:
- Structure and cap table
- 8 directors & officers
- 21 filings and events
- 1 underwriters
- 5 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Eli D. Casdin | 47 | CEO and Director |
| Keith A. Meister | 47 | Chairman |
| Brian Emes | 47 | CFO and Secretary |
| Shaun Rodriguez | 42 | CSO |
| Munib Islam | 46 | Director |
| Sean George | 46 | Director |
| Emily Leproust | 47 | Director |
| Nat Turner | 34 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Jefferies | BR | 38,500,000 | units |
| 38,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.